BXTAccelyon

Protected: Low dose rate brachytherapy for localised carcinoma of the prostate

By BXTAccelyon August 11, 2021 No Comments

About Author

BXTAccelyon

BXTAccelyon (BXTA) is the leading low-dose rate brachytherapy (LDR-B) partner to hospitals and clinics worldwide, and distribution partner for the PrecisionPoint™ freehand transperineal prostate biopsy system.

This post is password protected. Enter the password to view comments.

About Author

Related Posts

New research highlights wide variation in prostate cancer testing between GP practices

Study shows urine test for prostate cancer could be used at home

Trial finds stereotactic radiation therapy helps delay toxic forms of treatments for men with advanced prostate cancer